Michael Rosenblum, Ph.D.
Immunopharmacology and Targeted Therapy Laboratory
The Immunopharmacology and Targeted Therapy (ITT) laboratory, under the direction of Michael Rosenblum, Ph.D., is focused on the development of novel, targeted therapeutic agents. The ITT laboratory has developed a number of patent-protected highly cytotoxic proteins for inclusion into constructs containing cell-targeting proteins.
The laboratory is devoted to designing, expressing, and characterizing chimeric proteins targeting a wide range of cell-surface antigens present on tumor cells and tumor neovasculature. Well over 20 chimeric molecules have been developed targeting, leukemia, lymphoma, melanoma, breast, colon, lung and tumor neovasculature. Additional molecules targeting other tumor types are also under development.
The laboratory is adept at the full range of pre-clinical as well as clinical needs for the in vitro and in vivo characterization of these molecules and has an impressive track record of development. The ITT laboratory works in tight collaboration with numerous academic and commercial groups around the world to develop these exciting new agents.